Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing doc
For Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming. Ahead of an advisory committee meeting slated for Friday, the FDA on Wednesday unleashed damning ...
The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share. The deal stands a very good chance of being ...
It looks like Intercept Pharmaceuticals’ Ocaliva still has a tough road ahead in nonalcoholic steatohepatitis (NASH) after a panel of FDA advisers voiced concerns with the company's application ...
Failing to gain a potentially lucrative FDA approval to treat nonalcoholic steatohepatitis (NASH) was a blow to Intercept Pharmaceuticals. The new Jersey-based company still is working to get Ocaliva ...
In a memo promising legal immunity for those who kill alleged drug traffickers, the Trump administration floated an unusual ...
Intercept Pharmaceuticals reported 2023 Q1 earnings today. The company missed Wall Street's revenue estimate for the three-month period by approximately $4.7 million. The more important issue is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback